27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In South Korea, digital literacy education programs are expected to help its older population participate in online welfare services to increase their social support, self-esteem and well-being. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Language in patients with Alzheimer's disease has been extensively studied, with the exception of non-literal language comprehension. 1 key finding →
Participants: 39 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Elderly people affected by Mild Cognitive Impairment (MCI) usually report a perceived decline in cognitive functions that deeply impacts their quality of life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The machine learning algorithm for NPTs has suggested potential use as a reference in differentiating cognitive impairment in the clinical setting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregivers with higher mastery had less NE reactivity to the stressor task. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Nearly ¾ of the PD cohort reported falling after 8 years of follow-up. 1 key finding →
Participants: 32 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is the most common form of neurodegenerative dementia and its timely diagnosis remains a major challenge in biomarker discovery. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. 1 key finding →
Participants: 230 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We report the neuropathological findings in 32 patients, aged 46-86 years, with dementia lacking distinctive histopathology. 4 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Artificial intelligence (AI) is revolutionizing the field of medical imaging, offering unprecedented capabilities in data analysis, image interpretation, and decision support. 2 key findings →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper proposes a novel LLM-aided feature engineering approach that enhances interpretability by extracting clinically relevant features from the Oxford Textbook of Medicine. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Representations of White-racialized older adults were 5-fold higher than those of other races in both years. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCI prevalence was comparable across groups (7.5%-8.0%), but progression to dementia varied (9.4% Black vs. 11.4% Other). 5 key findings →
Participants: 83,180 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Modern machine learning and linguistic analysis will be increasingly useful in assessment and clustering of suspected AD. 1 key finding →
Participants: 167 Evidence: low
Full summary, score breakdown and related studies → Original source
In addition to Aβ and tau, ANXA5, VGF, GPM6A, and ACTZ are new signature proteins in AD EVs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The early detection of subjects with probable Alzheimer's disease (AD) is crucial for effective appliance of treatment strategies. 1 key finding →
Participants: 116 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD) is a progressive neurodegenerative disease where biomarkers for disease based on pathophysiology may be able to provide objective measures for disease diagnosis and staging. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The temporal analysis of spontaneous speech can be exploited in implementing a new, automatic detection-based tool for screening MCI for the community. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropathologists assess vast brain areas to identify diverse and subtly-differentiated morphologies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The CPCSSN diagnostic algorithms showed excellent sensitivity and specificity for hypertension, diabetes, epilepsy, and parkinsonism and acceptable values for the other conditions. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Multiple EHR components provide a more consistent and higher performance than a single one for the selected phenotypes. 5 key findings →
Participants: 175 Evidence: low
Full summary, score breakdown and related studies → Original source
The Ministry of Health, Labor, and Welfare, Japan, launched the Diagnosis Procedure Combination system in 2002. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the pathophysiology of which is very complex and largely unknown. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →